DocGo Inc. (NASDAQ:DCGO) Receives Average Rating of “Buy” from Analysts

Shares of DocGo Inc. (NASDAQ:DCGO) have earned a consensus recommendation of “Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $10.83.

Several equities research analysts have recently weighed in on DCGO shares. Stifel Nicolaus decreased their price target on DocGo from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, April 10th. Needham & Company LLC decreased their price target on DocGo from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Cantor Fitzgerald decreased their price target on DocGo from $13.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, February 29th. BTIG Research decreased their price target on DocGo from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, April 10th. Finally, Canaccord Genuity Group decreased their price objective on shares of DocGo from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, April 11th.

DocGo Stock Performance

Shares of DocGo stock opened at $3.50 on Friday. DocGo has a 52-week low of $2.78 and a 52-week high of $10.82. The stock’s 50-day simple moving average is $3.72 and its 200 day simple moving average is $4.61. The stock has a market capitalization of $364.60 million, a P/E ratio of 50.00, a P/E/G ratio of 0.36 and a beta of 0.91.

DocGo (NASDAQ:DCGO) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.07). DocGo had a net margin of 1.10% and a return on equity of 2.01%. The company had revenue of $199.25 million for the quarter, compared to the consensus estimate of $195.48 million. Equities research analysts forecast that DocGo will post 0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael J. Burdiek acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average cost of $3.61 per share, for a total transaction of $36,100.00. Following the completion of the transaction, the director now owns 571,595 shares in the company, valued at $2,063,457.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.78% of the stock is owned by company insiders.

Institutional Trading of DocGo

Several hedge funds and other institutional investors have recently bought and sold shares of DCGO. AJOVista LLC purchased a new stake in DocGo in the fourth quarter worth approximately $25,000. Victory Capital Management Inc. purchased a new stake in DocGo in the third quarter worth approximately $55,000. Cape Investment Advisory Inc. purchased a new stake in DocGo in the fourth quarter worth approximately $63,000. Envestnet Portfolio Solutions Inc. purchased a new stake in DocGo in the third quarter worth approximately $67,000. Finally, Worth Venture Partners LLC boosted its stake in shares of DocGo by 36.3% during the third quarter. Worth Venture Partners LLC now owns 16,028 shares of the company’s stock valued at $85,000 after purchasing an additional 4,265 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.